The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

Diagnosed with stage 4 lung cancer in 2020, Sanjay Dutt turned to chemotherapy, exercise, and family support in his fight ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

Amplia Therapeutics and Immutep have released clinical trial results that promise more effective treatments for pancreatic and lung cancers ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, together with its esteemed partners Heidelberg University Hospital, European Institute of ...

The U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie Inc.’s (NYSE:ABBV) Emrelis (telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, ...

Heidelberg, Germany, Milan, Seville, Spain and Binyamina, Israel (OTE) - A European-led consortium comprising Heidelberg University Hospital ( UKHD), the European Institute of Oncology (IEO), Virgen ...

AbbVie has received accelerated approval from the U.S. Food and Drug Administration (FDA) for EMRELIS (telisotuzumab ...